LvK Travel expenses from EASL and Falk Foundation. MM declares consultant honorary from Boehringer Ingelheim, Ipsen, Madrigal Pharmaceuticals; Speaker honorarium from AbbVie, AstraZeneca, Daiichi Sankyo, Gilead Sciences, GSK, Ipsen and NovoNordisk; Travel support: Abbvie, Boehringer Ingelheim, Gilead Sciences, Ipsen, Mirum and NovoNordisk. NA has received grant/research support from 89bio, Akero Therapeutics, Arbutus Biopharma, AstraZeneca, BioAge, Boehringer Ingelheim, Bristol Myers Squibb, Corcept Therapeutics, Galectin Therapeutics, Genentech, Gilead Sciences, Hepagene Therapeutics, Intercept Pharmaceuticals, Inventiva Pharma, Ionis Pharmaceuticals, Ipsen, Lilly, Madrigal Pharmaceuticals, Merck, NGM Biopharmaceuticals, NorthSea Therapeutics, Novo Nordisk, Perspectum, Pfizer, PharmaIN, Poxel, Regeneron, Viking Therapeutics, and Zydus Pharmaceuticals; reports speaker’s fees from AbbVie, AstraZeneca, Echosens, Gilead Sciences, Ipsen, Madrigal Pharmaceuticals, Novo Nordisk, and Perspectum; and reports consulting for 89bio, AbbVie, Akero, Boehringer Ingelheim, Echosens, Fibronostics, Gilead Sciences, HistoIndex, Intercept Pharmaceuticals, Ipsen, LiverRight, Madrigal Pharmaceuticals, NorthSea Therapeutics, Novo Nordisk, Perspectum, Pfizer, Regeneron, and Sonicy Incytes. JMS declares consultant honorary from Akero, Alentis, Alexion, Altimmune, Astra Zeneca, 89Bio, Bionorica, Boehringer Ingelheim, Gilead Sciences, GSK, HistoIndex, Ipsen, Inventiva Pharma, Madrigal Pharmaceuticals, Kríya Therapeutics, Lilly, eTherapeutics, Merck, MSD Sharp & Dohme GmbH, Nordic Bioscience, Northsea Therapeutics, Novartis, Novo Nordisk, Pfizer, Roche, Sanofi, Siemens Healthineers, Summit Clinical, and Vantage Biosciences Research; speaker honorarium from AbbVie, Boehringer Ingelheim, Gilead Sciences, Ipsen Novo Nordisk, Madrigal Pharmaceuticals, Worldwide Clinical Trials, Stockholder options: Hepta Bio. WPB received speakers fees for Eli Lilly, is part of the advisory board of Novo Nordisk and participates in trials of 89BIO, Boehringer Ingelheim, Novo Nordisk, and Inventiva Pharma. The authors report no other conflicts of interest in this work.
PubMed
